Compounded Semaglutide: What You Need to Know Before You Buy

What does 'compounded' mean for a drug like semaglutide?

Compounding is the preparation of a customized medication for a specific patient by a licensed pharmacy. It has a legitimate place in medicine — for patients who need a dose the manufacturer does not make, who have an allergy to an inactive ingredient, or who need a liquid formulation. Compounded medications are not FDA-approved: they have not gone through the agency's process for verifying safety, efficacy, and manufacturing quality. Instead, they are regulated primarily by state pharmacy boards, which vary considerably in their oversight rigor.

Under the Drug Quality and Security Act, two separate pathways exist:

• 503A pharmacies are traditional compounding pharmacies licensed by individual states. They must compound for specific, identified patients with a valid prescription. They are not subject to federal current Good Manufacturing Practice (cGMP) standards.
• 503B outsourcing facilities are registered with the FDA, must follow cGMP, are subject to FDA inspection, and may compound in larger quantities — but still cannot produce an "essentially a copy" of a commercially available FDA-approved drug. 1Ref 1U.S. Food and Drug Administration (2025).FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.Background on 503A/503B regulatory framework, shortage resolution timeline, and wind-down deadlines for compounded semaglutide and tirzepatide.

Why did compounded GLP-1 medications become so widespread?

When GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — became widely used for weight management and diabetes, supply could not keep pace with demand. Brand-name list prices exceeded $1,000 per month, and most insurance plans did not cover them for weight loss. During active FDA-declared shortage periods, federal rules permitted compounding pharmacies to legally produce these drugs at prices typically ranging from $150 to $300 per month. 1Ref 1U.S. Food and Drug Administration (2025).FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.Background on 503A/503B regulatory framework, shortage resolution timeline, and wind-down deadlines for compounded semaglutide and tirzepatide.

The FDA declared the semaglutide shortage resolved in February 2025 and provided a 90-day wind-down window — through May 22, 2025 — for 503B outsourcing facilities to stop compounding "essentially copies" of the now commercially available products. The FDA has since proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, with a public comment period open through June 2026. 1Ref 1U.S. Food and Drug Administration (2025).FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.Background on 503A/503B regulatory framework, shortage resolution timeline, and wind-down deadlines for compounded semaglutide and tirzepatide. The legal landscape continues to change; a product that was legally available a year ago may not be today, and the converse is also possible.

While the shortage period was active, IQVIA data showed compounded semaglutide led compounded GLP-1 prescriptions, and more than 80% of compounded GLP-1 prescriptions included supplemental additives — such as B vitamins or levocarnitine — whose safety in combination with semaglutide has not been studied.

What specific safety problems has the FDA documented?

The FDA's safety concerns about compounded GLP-1 products are specific and documented — not theoretical.

Dosing errors leading to hospitalizations. In July 2024, the FDA issued a formal alert after receiving reports of adverse events, some requiring hospitalization, that were attributable to dosing errors with compounded semaglutide injectable products dispensed in multidose vials. Patients drew more than the prescribed dose — in some cases 5 to 20 times the intended amount. Reported adverse events included nausea, vomiting, abdominal pain, fainting, dehydration, acute pancreatitis, and gallstones. As of April 30, 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. 2Ref 2U.S. Food and Drug Administration (2024).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; and FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.Specific documented adverse events: dosing errors 5-20x intended dose, hospitalizations, unapproved salt forms, sterility failures, 520 adverse event reports for compounded semaglutide as of April 2025, and 900+ FAERS cases including 17 deaths as of end of 2024.

Unapproved salt forms of the active ingredient. The FDA documented that some compounders were using semaglutide sodium or semaglutide acetate — salt forms that are chemically different from the base form of semaglutide used in FDA-approved products. These salts have not been shown to be safe or effective, and no evidence establishes that they are pharmacologically equivalent to Ozempic or Wegovy. 2Ref 2U.S. Food and Drug Administration (2024).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; and FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.Specific documented adverse events: dosing errors 5-20x intended dose, hospitalizations, unapproved salt forms, sterility failures, 520 adverse event reports for compounded semaglutide as of April 2025, and 900+ FAERS cases including 17 deaths as of end of 2024.

Contamination and sterility failures. The FDA warned against products from facilities where sterility could not be assured. Injection of a non-sterile drug intended to be sterile can result in serious, potentially life-threatening infections including sepsis. In August 2024, more than 15,000 vials of compounded semaglutide and tirzepatide were recalled from a single 503B facility due to lack of assurance of sterility. 2Ref 2U.S. Food and Drug Administration (2024).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; and FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.Specific documented adverse events: dosing errors 5-20x intended dose, hospitalizations, unapproved salt forms, sterility failures, 520 adverse event reports for compounded semaglutide as of April 2025, and 900+ FAERS cases including 17 deaths as of end of 2024.

Warning letters at scale. In September 2025, the FDA issued more than 50 warning letters to U.S. and international companies compounding or manufacturing GLP-1 drugs, targeting false and misleading promotional claims alongside regulatory violations. 2Ref 2U.S. Food and Drug Administration (2024).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; and FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.Specific documented adverse events: dosing errors 5-20x intended dose, hospitalizations, unapproved salt forms, sterility failures, 520 adverse event reports for compounded semaglutide as of April 2025, and 900+ FAERS cases including 17 deaths as of end of 2024.

As of late 2024, the FDA's Adverse Event Reporting System listed more than 900 adverse health events associated with compounded semaglutide and tirzepatide, including 17 deaths. Causality cannot always be established from adverse event reports, and unreported events likely outnumber those submitted — but the volume and pattern are clinically meaningful. 2Ref 2U.S. Food and Drug Administration (2024).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; and FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.Specific documented adverse events: dosing errors 5-20x intended dose, hospitalizations, unapproved salt forms, sterility failures, 520 adverse event reports for compounded semaglutide as of April 2025, and 900+ FAERS cases including 17 deaths as of end of 2024.

How do the risks of compounded GLP-1s differ from the brand-name versions?

FDA-approved semaglutide (Wegovy, Ozempic) carries its own documented risks that apply regardless of formulation. The approved prescribing information carries a boxed warning for thyroid C-cell tumors observed in rodent studies; semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN-2). 3Ref 3Kommu S, Whitfield P (2024).Semaglutide.FDA-approved indications (Wegovy BMI ≥30 or ≥27 with comorbidity), contraindications including medullary thyroid carcinoma and MEN-2 boxed warning, and adverse effect profile including GI events and gallbladder disorders. Common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal pain; in the pivotal STEP 1 trial, 4.5% of semaglutide-treated patients discontinued due to gastrointestinal events. 4Ref 4Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: mean 14.9% body weight reduction vs 2.4% placebo at 68 weeks; 4.5% discontinued due to GI events; gallbladder events including cholelithiasis documented. Gallbladder events including cholelithiasis (gallstones) occurred at roughly twice the rate of placebo in STEP 1. 4Ref 4Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: mean 14.9% body weight reduction vs 2.4% placebo at 68 weeks; 4.5% discontinued due to GI events; gallbladder events including cholelithiasis documented.

The large SELECT cardiovascular outcomes trial enrolled 17,604 adults with obesity and established cardiovascular disease (but without diabetes) and found that weekly semaglutide 2.4 mg significantly reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke versus placebo over roughly 40 months. 5Ref 5Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. (SELECT Trial Investigators) (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial (n=17,604): semaglutide 2.4 mg weekly significantly reduced composite of cardiovascular death, nonfatal MI, or nonfatal stroke vs placebo over ~40 months in adults with obesity and established cardiovascular disease but without diabetes.

Compounded GLP-1 products carry all of the above risks and add a distinct layer: - Potentially different active ingredient (salt form rather than base form) - No verified potency — the labeled dose may not match actual drug content - Greater risk of sterility failure for injectable products - No standardized dose delivery; multidose vials require manual calculation - No post-market pharmacovigilance system equivalent to the FDA MedWatch infrastructure that monitors approved products

How do you evaluate a compounding pharmacy if a prescriber recommends one?

If a licensed clinician determines a compounded GLP-1 is appropriate for your specific situation, look for a pharmacy that meets all of the following criteria:

1. State-licensed in the state where it is operating and where you are located 2. Registered as a 503B outsourcing facility with the FDA (a meaningfully higher regulatory bar than 503A: subject to cGMP, FDA inspection, and adverse event reporting obligations) 3. Requires a valid prescription from a licensed prescriber — not a questionnaire, not a "clinical consult" with an undisclosed clinician 4. Uses third-party testing and will provide Certificates of Analysis confirming potency, purity, and sterility for the specific lot dispensed 5. Provides a prefilled, ready-to-inject syringe rather than requiring you to draw and calculate the dose yourself from a multidose vial

Pharmacies that sell GLP-1 medications without a prescription, ship nationwide from a single location without state licensing in each destination state, market primarily through social media influencers, or refuse to provide testing documentation are high-risk sources. The FDA maintains a public 503B outsourcing facility registration database, which is a reasonable starting point for verification.

What should you talk through with your clinician before making any decision?

Your primary care clinician or an obesity medicine specialist is the right starting point before pursuing any GLP-1 medication — compounded or brand-name. They can:

• Establish whether a GLP-1 is medically appropriate for you (there are absolute contraindications including MEN-2 and personal or family history of medullary thyroid carcinoma)
• Review your full medication list for interactions and your medical history for conditions that affect candidacy (including a history of pancreatitis or gallbladder disease)
• Determine whether insulin or other agents are better suited if diabetes management is the primary goal
• Explore whether insurance coverage or manufacturer patient assistance programs might make the FDA-approved drug accessible, before assuming compounding is the only affordable path
• If they do recommend a compounded version — direct you to a specific, vetted pharmacy and provide dosing instructions clearly in milligrams, not "units"

GLP-1 receptor agonists require clinical supervision throughout — not just a one-time prescription. Side effects, dose titration, and monitoring for complications require follow-up that a telehealth prescriber who issues a prescription after a brief questionnaire typically does not provide.